Sterling Capital Management’s Five Prime Therapeutics, Inc. FPRX Stock Holding History

Sterling Capital Management’s Portfolio FPRX Stock Details FPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-23,095	Closed	-$835K	–	1032
2017 Q1	$835K	Buy	23,095 +4,417	+24%	+$195K	0.01%	672
2016 Q4	$936K	Buy	18,678 +3,445	+23%	+$181K	0.01%	605
2016 Q3	$800K	Buy	15,233 +2,022	+15%	+$96.6K	0.01%	587
2016 Q2	$546K	Buy	+13,211	New	+$575K	0.01%	721

Other funds holding FPRX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Sterling Capital Management's FPRX Position: Q2 2017 in Review

Sterling Capital Management sold out of Five Prime Therapeutics, Inc. (FPRX) in Q2 2017, closing a stake of 23,095 shares — an estimated $835K sold.

Sterling Capital Management first reported a position in FPRX in Q2 2016 and held it in 4 quarters. The position peaked at $936K in Q4 2016. 123 funds tracked by Wall St. Rank hold FPRX as of Q2 2017.

Sterling Capital Management reported no remaining Five Prime Therapeutics, Inc. position as of Q2 2017 after selling out during the quarter.
Sterling Capital Management sold 23,095 Five Prime Therapeutics, Inc. shares in Q2 2017, an estimated $835K.
Sterling Capital Management first reported a position in Five Prime Therapeutics, Inc. in Q2 2016 and held it in 4 quarters.
Sterling Capital Management's Five Prime Therapeutics, Inc. position peaked at $936K in Q4 2016.
123 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q2 2017.

Based on Sterling Capital Management's 13F filing for Q2 2017, filed 15 Aug 2017.